PTC Therapeutics, a biotech targeting rare forms of muscular dystrophy and cystic fibrosis, raised $126 million by offering 8.4 million shares at $15.00, within the range of $13.00 to $16.00. PTC Therapeutics plans to list on the NASDAQ under the symbol PTCT. PTC Therapeutics initially filed confidentially on 3/18/2013. J.P. Morgan and Credit Suisse acted as lead managers on the deal.
